Skip to main content
SpringerLink
Log in

Letter to the Editor Regarding Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently-Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands

  • Letter
  • Published:
Advances in Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Serné EH, Roze S, Buompensiere MI, Valentine WJ, Portu SD, de Valk HW. Cost-effectiveness of hybrid closed loop insulin pumps versus multiple daily injections plus intermittently scanned glucose monitoring in people with type 1 diabetes in the Netherlands. Adv Ther. 2022;39:1844–56.

    Article  PubMed  Google Scholar 

  2. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22:583–9.

    Article  CAS  PubMed  Google Scholar 

  3. Charleer S, Block CD, Huffel LV, Broos B, Fieuws S, Nobels F, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43:389–97.

    Article  PubMed  Google Scholar 

  4. Evans M, Welsh Z, Ells S, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022. https://doi.org/10.1007/s13300-022-01253-9

    Article  CAS  PubMed  Google Scholar 

  5. Fokkert M, Dijk P van, Edens M, Barents E, Mollema J, Slingerland R, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7:e000809. doi:https://doi.org/10.1136/bmjdrc-2019-000809

  6. Leelarathna L, Evans ML, Neupane S, Rayman G, Lumley S, Cranston I, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. New Engl J Med. 2022;387:1477–87.

    Article  CAS  PubMed  Google Scholar 

  7. Nørgaard K, Scaramuzza A, Bratina N, Lalić NM, Jarosz-Chobot P, Kocsis G, et al. Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther. 2013;15:273–80.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hayek AAA, Robert AA, Dawish MAA. Evaluation of freestyle libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10:1179551417746957.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Boscari F, Ferretto S, Cavallin F, Fadini GP, Avogaro A, Bruttomesso D. Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care. Acta Diabetol. 2022;1–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Visser MM, Charleer S, Fieuws S, De Block C, Hilbrands R, Van Huffel L, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397(10291):2275–83. https://doi.org/10.1016/S0140-6736(21)00789-3.

    Article  CAS  PubMed  Google Scholar 

  11. McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17:714–24.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding

All funding for the preparation of this Letter to the Editor was provided by Abbott Laboratories Ltd.

Editorial Assistance 

Assistance in the preparation of this Letter to the Editor was provided by Dr. Robert Brines of Bite Medical Consulting.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

All named authors contributed to the concept and design of the manuscript and worked collaboratively to review and prepare the final manuscript.

Disclosures

Fleur Levrat-Guillen and Patricia De Cock are full-time employees of Abbott.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Author information

Authors and Affiliations

  1. Abbott Laboratories Ltd, Abbott House, Vanwall Business Park, Maidenhead, Berkshire, SL6 4XE, UK

    Fleur Levrat-Guillen

  2. Abbott Laboratories Ltd, Abbott Offices, Av. Einstein 14, 1300, Wavre, Belgium

    Patricia De Cock

Authors
  1. Fleur Levrat-Guillen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia De Cock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fleur Levrat-Guillen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levrat-Guillen, F., De Cock, P. Letter to the Editor Regarding Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently-Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands. Adv Ther 40, 2542–2544 (2023). https://doi.org/10.1007/s12325-023-02427-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-023-02427-y

Keywords

Search

Navigation